Skip to main content

Search articles in

Found 3,024 articles

  • Bionical Solutions Appoints Chief Technology Offic

    Bionical Solutions Appoints Chief Technology Officer to Create Innovative Data Products and Software for the Digital Business

    • 29 Feb 2024
    • Editor

    Bionical Solutions, a leading provider of technology enabled engagement and healthcare services to global pharmaceutical, biotech, healthcare companies and the NHS, today announced the appointment of Andrew Seward as Chief Technology Officer for the Digital business.

  • BC Platforms Announces Executive Leadership Change

    BC Platforms Announces Executive Leadership Changes

    • 29 Feb 2024
    • Editor

    BC Platforms AG (hereafter "BC Platforms") today announces that Tero Silvola, current CEO, is leaving the company, effective today. A new Executive office has been formed with current COO, Mikaela Bruhammar, appointed as interim CEO, together with CFO Kaj Työppönen.

  • Greenphire Adds Industry Veteran  Dan Shannon as N

    Greenphire Adds Industry Veteran Dan Shannon as New Chief Experience Officer

    • 29 Feb 2024
    • Editor

    Greenphire, a leading innovator in software solutions for improving clinical research site performance and participant satisfaction, today announced the addition of healthcare technology executive Dan Shannon as its new Chief Experience Officer (CXO). As CXO, he will oversee service delivery and steward the journey of continuous evolution toward an optimal client experience from beginning to end.

  • About Mestag Therapeutics

    About Mestag Therapeutics

    • 29 Feb 2024
    • Editor

    Mestag harnesses new insights into fibroblast-immune interactions to develop impactful treatments for patients. We are progressing a pipeline of sophisticated first-in-class antibodies designed to improve the lives of patients with cancer and inflammatory disease.

  • Aston Pharmacy School students benefit from genera

    Aston Pharmacy School students benefit from generative AI simulation to prepare them for the real world

    • 29 Feb 2024
    • Editor

    Aston Pharmacy School has introduced new generative artificial intelligence (AI) simulation software to train students in common situations they will encounter in practice and ensure they are properly prepared for their pharmacy placements.

  • Over a Third of Job Applicants Use ChatGPT When Ap

    Over a Third of Job Applicants Use ChatGPT When Applying for a Job

    • 29 Feb 2024
    • Editor

    Hays, the world’s specialist leader in workforce solutions and recruitment, asked over 15,000 respondents whether they had used ChatGPT when applying for a job, 39% said they had used the generative AI tool to help with their CV/resume, which is a 13% increase from 2023.

  • Novavax’s Protein-based Non-mRNA COVID-19 Vaccine

    Novavax’s Protein-based Non-mRNA COVID-19 Vaccine Available Now as Additional Dose for Individuals Aged 65 and Older Following U.S. CDC Advisory Committee Recommendation

    • 29 Feb 2024
    • Editor

    Today, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor (11 to 1; 1 abstain) to recommend that individuals aged 65 and older should receive an additional dose of 2023-2024 Formula COVID-19 vaccine (four months since receipt of the last dose).

  • PharmAust announces positive Phase 1 MEND Study To

    PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS

    • 29 Feb 2024
    • Editor

    PharmAust Limited (ASX: PAA & PAAOA) ("PharmAust" or "the Company"), a clinical-stage biotechnology company, is pleased to announce that it has met its primary safety and tolerability endpoints with monepantel (MPL) and, importantly, demonstrated a positive signal of potential efficacy.

  • Ethics and GCP Forum

    Ethics and GCP Forum

    • 28 Feb 2024
    • PharmiWeb Editor

    The Institute of Clinical Research is delighted to announce the Spring Ethics and GCP Forum which will be in person on Friday 19th April at University College London.

  • About RSSL

    About RSSL

    • 28 Feb 2024

    RSSL is a cutting-edge contract research organisation, pushing the boundaries of science and innovation to help make our world safer, healthier and more sustainable

  • Curia Appoints Steve Lavezoli as Vice President, B

    Curia Appoints Steve Lavezoli as Vice President, Biologics

    • 28 Feb 2024
    • Editor

    Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26. Lavezoli will lead Curia’s biologics division, overseeing its discovery, development and manufacturing services.

  • About Curia

    About Curia

    • 28 Feb 2024
    • Editor

    Curia is a Contract Development and Manufacturing Organization (CDMO) with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with biopharmaceutical customers to bring life-changing therapies to market. Our biologics and small molecule offerings span discovery through commercialization, with integrated regulatory and analytical capabilities.

  • A Recruiter’s Guide to Hiring a Pharmaceutical Pro

    A Recruiter’s Guide to Hiring a Pharmaceutical Product Manager

    • 28 Feb 2024
    • Lucy Walters

    In this guide, we explore the essential steps and considerations for you to keep in mind when searching for a pharmaceutical product manager. From understanding the unique demands of the role to identifying key competencies and conducting effective interviews, this guide will provide you with valuable tips to help you focus your candidate search and engage top talent.

  • About TrakCel

    About TrakCel

    • 28 Feb 2024
    • PharmiWeb Editor

    TrakCel is the market leading developer of integrated cell orchestration solutions and services.

  • Kalderos Attracts Two Recognized Industry Leaders

    Kalderos Attracts Two Recognized Industry Leaders to Board of Directors

    • 27 Feb 2024
    • Editor

    Data infrastructure and analytics company Kalderos, creator of the world's first Drug Discount Management platform, today announced the addition of two experienced and highly respected industry veterans to its board of directors.

  • About Curve Therapeutics

    About Curve Therapeutics

    • 27 Feb 2024
    • PharmiWeb Editor

    Curve Therapeutics is a private biotechnology company pioneering a revolutionary intracellular screening platform to enable the discovery of innovative therapeutics that address complex and challenging disease targets with the potential to transform the lives of patients

  • U.S. FDA Approves Expanded Indication for Gilead’s

    U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance

    • 27 Feb 2024
    • Editor

    Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved a new, expanded indication for Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. HIV treatment resistance is permanent and irreversible, which can jeopardize future treatment options for PWH.

  • Survodutide Phase II trial shows 83% of adults tre

    Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

    • 27 Feb 2024
    • Editor

    Boehringer Ingelheim today announced that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%) in a Phase II trial [response difference: 64.8% (CI 51.1% - 78.6%), p<0.0001].2

  • GSK announces positive headline results from EAGLE

    GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC)

    • 27 Feb 2024
    • Editor

    GSK plc (LSE/NYSE: GSK) today announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhoea in adolescents and adults.

  • Voydeya recommended for approval in the EU by CHMP

    Voydeya recommended for approval in the EU by CHMP as add-on treatment to ravulizumab or eculizumab for adults with PNH who have residual haemolytic anaemia

    • 27 Feb 2024
    • Editor

    Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia.